

5.4.1 - Appendix 1: Published policies (16) (1 April 2025 –18 September 2025)

Policy Number	Title	Commissioning Team	Publication date
CP50	POSITRON EMISSION TOMOGRAPHY (PET), COMMISSIONING POLICY [UPDATE]	CANCER AND BLOOD	12 September 2025
PPS167	EMICIZUMAB AS PROPHYLAXIS IN PEOPLE WITH CONGENITAL HAEMOPHILIA A WITH FACTOR VIII INHIBITORS (ALL AGES), POLICY POSITION STATEMENT [UPDATE]	CANCER AND BLOOD	12 September 2025
CP221	RECREATIONAL AND SPORT PROSTHETICS FOR PEOPLE UNDER THE AGE OF 25 YEARS, COMMISSIONING POLICY [UPDATE]	NEUROSCIENCES AND LONG-TERM CONDITIONS	12 September 2025
PPS191	NUSINERSEN FOR TREATING CHILDREN UP TO 17 YEARS WITH SPINAL MUSCULAR ATROPHY, POLICY POSITION STATEMENT [UPDATE]	WOMEN AND CHILDREN	5 September 2025
PPS217	VOLANESORSEN FOR TREATING FAMILIAL CHYLOMICRONAEMIA SYNDROME, POLICY POSITION STATEMENT [UPDATE]	WOMEN AND CHILDREN	5 September 2025
CP55	DRUG TREATMENT FOR LYSOSOMAL STORAGE DISORDERS (ALL AGES), COMMISSIONING POLICY [UPDATE]	WOMAN AND CHILDREN	8 August 2025
SS169	PAEDIATRIC NEPHROLOGY, SERVICE SPECIFICATION [UPDATE]	WOMEN AND CHILDREN	8 August 2025
PPS308	EVINACUMAB FOR TREATING HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA IN PEOPLE 12 YEARS AND OVER, POLICY POSITION STATEMENT [NEW]	WOMEN AND CHILDREN	8 August 2025
SS205	CARDIAC SURGERY, SERVICE SPECIFICATION [NEW]	CARDIAC	8 August 2025
SS183	RADIOFREQUENCY ABLATION (RFA) IN THE MANAGEMENT OF BARRETT'S OESOPHAGUS IN ADULTS ,SERVICE SPECIFICATION [UPDATE]	CANCER AND BLOOD	18 June 2025

CP183	RADIOFREQUENCY ABLATION (RFA) IN THE MANAGEMENT OF BARRETT'S OESOPHAGUS IN ADULTS, COMMISSIONING POLICY [UPDATE]	CANCER AND BLOOD	18 June 2025
CP297	VASCULAR ACCESS, COMMISSIONING POLICY [NEW] [NEW]	WELSH KIDNEY NETWORK	18 June 2025
SS297	VASCULAR ACCESS, SERVICE SPECIFICATION [NEW]	WELSH KIDNEY NETWORK	18 June 2025
PPS203	DRUG TREATMENTS FOR SEIZURES ASSOCIATED WITH DRAVET SYNDROME OR LENNOX-GASTAUT SYNDROME IN PEOPLE AGED 2 YEARS AND OLDER, POLICY POSITION STATEMENT [UPDATE]	WOMEN AND CHILDREN	17 April 2025
PPS306	TAFAMIDIS FOR TREATING TRANSYTHRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY, POLICY POSITION STATEMENT [NEW]	CARDIAC	11 April 2025
PPS298	SETMELANOTIDE FOR TREATING OBESITY AND HYPERPHAGIA IN BARDET-BIEDL SYNDROME, POLICY POSITION STATEMENT [NEW]	WOMEN AND CHILDREN	11 April 2025